Stock Research: Ajanta Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Ajanta Pharma

NSEI:AJANTPHARM INE031B01049
78
  • Value
    67
  • Growth
    81
  • Safety
    Safety
    39
  • Combined
    78
  • Sentiment
    58
  • 360° View
    360° View
    78
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Ajanta Pharma Limited is an India-based specialty pharmaceutical company providing a comprehensive range of branded generic products. It operates in therapeutic segments like cardiology, anti-diabetes, ophthalmology, dermatology, antibiotics, anti-malarial, pain, respiratory, gynecology, pediatric, and general health, with businesses in the United States generics and institutional segments in Africa. It is focused on branded generic businesses across India, Asia, and Africa. In the last fiscal year, the company had a market cap of $4076 millions, profits of $412 millions, revenue of $544 millions, and 9628 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 78 (better than 78% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Ajanta Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Ajanta Pharma. The consolidated Growth Rank has a good rank of 81, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 81% of competitors in the same industry. The consolidated Safety Rank at 67 means that the company has a financing structure that is safer than 67% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 58, which means that professional investors are more optimistic about the stock than for 58% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 39, meaning that the share price of Ajanta Pharma is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 61% of alternative stocks in the same industry. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
39 25 37 49
Growth
81 69 89 49
Safety
Safety
67 84 82 69
Sentiment
58 33 92 41
360° View
360° View
78 54 96 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
76 33 91 3
Opinions Change
45 7 50 50
Pro Holdings
n/a 34 80 100
Market Pulse
35 76 58 31
Sentiment
58 33 92 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
39 25 37 49
Growth
81 69 89 49
Safety Safety
67 84 82 69
Combined
78 78 93 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
45 32 49 53
Price vs. Earnings (P/E)
40 23 44 36
Price vs. Book (P/B)
30 23 38 44
Dividend Yield
37 37 29 56
Value
39 25 37 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
75 76 63 59
Profit Growth
55 43 76 28
Capital Growth
98 28 46 39
Stock Returns
47 93 93 71
Growth
81 69 89 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
87 90 88 92
Refinancing
39 36 38 26
Liquidity
63 82 78 76
Safety Safety
67 84 82 69

Similar Stocks

Discover high‑ranked alternatives to Ajanta Pharma and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.